Le Lézard
Classified in: Health, Business
Subjects: LIC, MAT

Aesthetics Biomedical® Inc. Announces Vivace® RF Microneedling Partnership With SkinCeuticals C E Ferulic For Newest In-Office Treatment Experience


PHOENIX, Oct. 1, 2020 /PRNewswire-PRWeb/ -- Aesthetics Biomedical® Inc., a leader in novel aesthetic products and devices, and SkinCeuticals, a leader in advanced skincare technology, announce the launch of the collaboration that combines Vivace® Microneedle RF with a post-treatment protocol featuring SkinCeuticals C E Ferulic for enhanced patient experience with minimally-invasive skin rejuvenation treatments.

To give patients visibly brighter, more radiant skin, Aesthetics Biomedical's industry leading, FDA-cleared, radiofrequency microneedling technology, Vivace® has partnered with the #1 professional skincare brand in the U.S., SkinCeuticals. A minimally-invasive treatment, Vivace® stimulates the natural production of collagen and has been shown by physicians to be effective in alleviating facial wrinkles, fine lines, improving skin texture, tightening and toning the face and neck for an overall glow. Uniquely designed for an incomparable, comfortable patient experience, only Vivace® boasts a precision robotic motor that brings maximum results with minimal discomfort compared to other devices.

Sheldon Larson, Chief Marketing Officer at Aesthetics Biomedical® who spearheaded this partnership initiative states "As two leading skincare powerhouses, partnering together allows us to really make an impact on overall skin health. Both physicians and patients will see the benefits it brings to their Vivace Experience® by extending the post-treatment care with SkinCeuticals hero product, C E Ferulic." Larson continues. "From an industry perspective, this relationship is disruptive, with ABM aligning with a brand that's a longtime industry mainstay like SkinCeuticals. We've forged our own path to bring the best skincare treatments, products and business practices to a wider audience for the ultimate benefit of our physicians."

For one day following patients' Vivace® RF Microneedling treatment, the skincare protocol for patients is now complemented with the use of SkinCeuticals C E Ferulic, the iconic daytime Vitamin C serum, proven to deliver advanced environmental protection and visible anti-aging results. C E Ferulic works to further enhance the Vivace Experience®, 24 hours post treatment and provides astonishing results after just one session. SkinCeuticals antioxidant formulations are the gold standard and results have shown a 44% improvement in skin radiance, 36% improvement in the appearance of wrinkles and 37% increase in skin firmness.

MaryAnn Guerra, CEO & President of Aesthetics Biomedical® adds, "Aesthetics Biomedical has always advocated for the best patient experience. That is why we created the Vivace Experience® to ensure not only a great treatment but to follow-through with that positive experience post treatment. The right treatment combined with the right products to ensure the best outcomes. It doesn't get better than Vivace® x SkinCeuticals."

On the partnership, SkinCeuticals General Manager, Christina Fair notes, "SkinCeuticals is thrilled to collaborate with Aesthetics Biomedical® to create this unique, innovative treatment that provides rejuvenation benefits and antioxidant protection." She continues, "This collaboration aligns with our goals to provide optimal patient outcomes through the synergy of SkinCeuticals scientifically-backed skincare and professional treatments."

Vivace Experience® featuring SkinCeuticals C E Ferulic can be found through skincare physicians nationwide; for locations and pricing visit VivaceExperience.com or SkinCeuticals.com. Follow along on social media or share your experience using #VivaCEFerulic and tagging @VivaceExperience & @SkinCeuticals.

ABOUT AESTHETICS BIOMEDICAL
Aesthetics Biomedical, Inc., headquartered in Phoenix, Ariz., is committed to the development and distribution of novel aesthetic devices, products, and services in the global market. Aesthetics Biomedical's innovation center is a leader in breakthrough technologies and combination therapies for its clients, physician network and the aesthetic arena, creating novel patient treatment experiences that benefit from ongoing research, approved clinical indications for use, as well as a personalized approach designed for consumer benefit. Visit AestheticsBiomedical.com or VivaceExperience.com.

CONTACTS:
Press Contact: Courtney Frappier: (214) 505-5173 / [email protected]
Marketing Contact: Sheldon Larson: (602) 682-6423 / [email protected]

 

SOURCE Aesthetics Biomedical


These press releases may also interest you

at 09:38
The Wyatt Foundation and The Conceive Fertility Foundation announce today a joint partnership that will award $15,000 grants to five individuals/couples who need in vitro fertility (IVF) to build their families. Launching during National Infertility...

at 09:38
New platform and surgery center investment adds advanced facility capabilities to specialty care network, strengthening in-person treatment and attracting leading orthopedic surgeons and physiciansWith Theater launch, value-based MSK care visionary...

at 09:32
GLOW Production, a leading cinematic development company in Malaysia, today announced it is opening its business to North American studios that have struggled to find sufficient international resources that can meet expedited pipelines and deliver...

at 09:30
Perma-Pipe International Holdings, Inc. announced today financial results for the fourth quarter and 2023 fiscal year ended January 31, 2024. "Net sales for the fourth quarter were $40.2 million, an increase of $3.8 million as compared to the same...

at 09:30
BRIX Holdings, LLC ("BRIX"), the multi-brand franchising portfolio group specializing in restaurant brands with superior products including Friendly's, Red Mango and Orange Leaf, announced today it has entered into a definitive agreement to acquire...

at 09:26
CNFinance Holdings Limited ("CNFinance" or the "Company"), a leading home equity loan service provider in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and...



News published on and distributed by: